Astana Biomed Group, an authorized Abcam distributor in Central Asia

Human KIF7 knockout HeLa cell lysate (ab258487)

Overview

  • Product name

    Human KIF7 knockout HeLa cell lysate

  • Product overview


    Knockout cell lysate achieved by CRISPR/Cas9.

  • Parental Cell Line

    HeLa

  • Organism

    Human

  • Mutation description

    Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon8 and 7 bp deletion in exon8.

  • Passage number

  • Knockout validation

    Sanger Sequencing

  • Reconstitution notes

    To use as WB control, resuspend the lyophilizate in 50 µL of LDS* Sample Buffer to have a final concentration of 2 mg/ml. For reducing conditions, we recommend a final concentration of 0.1 M DTT.

    *Usage of SDS sample buffer is not recommended with these lyophilized lysates.

  • Notes

    Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version - found here. Please refer to our lysis protocol for further details on how our lysates are prepared.

    User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

    Access thousands of knockout cell lysates, generated from commonly used cancer cell lines.
    See here for more information on knockout cell lysates.

    Abcam has not and does not intend to apply for the REACH Authorisation of customers’ uses of products that contain European Authorisation list (Annex XIV) substances.
    It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

    This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Properties

Target

  • Function

    Acts as both a negative and positive regulator of sonic hedgehog (Shh) pathway, acting downstream of SMO. Negatively regulates the pathway by preventing inappropriate activation of the transcriptional activator GLI2 in the absence of ligand. Positively regulates the pathway by preventing the processing of the transcription factor GLI3 into its repressor form. Required for efficient localization of GLI3 to cilia in response to Shh. May also act as a ciliary motor.

  • Tissue specificity

    Embryonic stem cells, melanotic melanoma and Jurkat T-cells.

  • Sequence similarities

    Belongs to the kinesin-like protein family. KIF27 subfamily.
    Contains 1 kinesin-motor domain.

  • Cellular localization

    Cell projection > cilium. SMO is required for its accumulation within cilia. Moves from the cilia base to the cilia tip in response to activation of the Shh pathway.
  • Information by UniProt

  • Alternative names

    • EQYK340
    • kif7
    • KIF7_HUMAN
    • kinesin family member 7
    • kinesin like protein KIF7
    • Kinesin-like protein kif7
    • UNQ340
    see all

Properties

Images

  • Sanger Sequencing - Human KIF7 knockout HeLa cell lysate (ab258487)
    Sanger Sequencing - Human KIF7 knockout HeLa cell lysate (ab258487)

    Allele-1: 7 bp deletion in exon8

     

  • Sanger Sequencing - Human KIF7 knockout HeLa cell lysate (ab258487)
    Sanger Sequencing - Human KIF7 knockout HeLa cell lysate (ab258487)

    Allele-2: 1 bp insertion in exon8

     

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Clear all

Recently viewed products

Sign up